Unexpected coreceptor usage of primary human immunodeficiency virus type 1 isolates from viremic patients under highly active antiretroviral therapy

Journal of Infectious Diseases

Volumn 181, Issue 2, 2000, Pages 513-521

  Holtkamp, Nikola ^a   Otteken, Ahlert ^a   Findhammer, Stephan ^b   Miller, Veronica ^b   Kurth, Reinhard ^a   Werner, Albrecht ^a  

^a PAUL EHRLICH INSTITUT   (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; VIRUS RNA;

ARTICLE; DRUG RESISTANCE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; VIREMIA; VIRUS INHIBITION; VIRUS LOAD;

AMINO ACID SEQUENCE; ANTI-HIV AGENTS; ANTIBODIES; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CHEMOKINES, CXC; COHORT STUDIES; DRUG THERAPY, COMBINATION; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; PEPTIDE FRAGMENTS; RECEPTORS, CHEMOKINE; RECEPTORS, CXCR4; RECEPTORS, HIV; SEQUENCE ANALYSIS, DNA; VIRAL LOAD; VIREMIA;

EID: 0034049667     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315240     Document Type: Article

References (49)

1. Roos MTL, Lange JMA, de Goede REY, et al. Viral phenotype and immune response in primary human immunodeficiency virus type 1 infection. J Infect Dis 1992; 165:427-32.
2. Valentin A, Albert J, Fenyoe EM, Asjoe B. Dual tropism for macrophages and lymphocytes is a common feature of primary human immunodeficiency virus type 1 and 2 isolates. J Virol 1994; 68:6684-9.
3. Dalgleish AG, Beverley PC, Clapham PR, Crawford DH, Greaves MF, Weiss RA. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 1984; 312:763-7.
4. Klatzmann D, Champagne E, Chamaret S, et al. T-lymphocyte T4 molecule behaves as receptor for human retrovirus LAV. Nature 1984; 312:767-78.
5. Maddon PJ, Dalgleish AG, McDougal J, Clapham PR, Weiss RA, Axel R. The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. Cell 1986; 47:333-48.
6. Trkola A, Dragic T, Arthos J, et al. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5 [see comments]. Nature 1996; 384:184-7.
7. Wu H, Myszka DG, Tendian SW, et al. Kinetic and structural analysis of mutant CD4 receptors that are defective in HIV gp120 binding. Proc Natl Acad Sci USA 1996; 93:15030-5.
8. Doms RW, Peiper SC. Unwelcomed guests with master keys: how HIV uses chemokine receptors for cellular entry. Virology 1997; 235:179-90.
9. Broder CC, Collman RG. Chemokine receptors and HIV. J Leukoc Biol 1997; 62:20-9.
10. Moore JP. Coreceptors: implications for HIV pathogenesis and therapy. Science 1997; 276:51-2.
11. Rucker J, Doms RW. Chemokine receptors as HIV coreceptors: implications and interactions. AIDS Res Hum Retroviruses 1998; 14(Suppl 3):S241-6.
12. Zhang L, He T, Huang Y, et al. Chemokine coreceptor usage by diverse primary isolates of human immunodeficiency virus type 1. J Virol 1998; 72:9307-12.
13. Alkhatib G, Combadiere C, Broder CC, et al. CC CKR5: a RANTES, MIP- lα, MIP-1β receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 1996; 272:1955-8.
14. Choe H, Farzan M, Sub Y, et al. The β-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 1996; 85:1135-8.
15. Deng H, Liu R, Ellmeier W, et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996; 381:661-6.
16. Doranz BJ, Rucker J, Yi Y, et al. A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR- 2b as fusion cofactors. Cell 1996; 85:1149-58.
17. + cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996; 381:667-73.
18. Rucker J, Samson M, Doranz BJ, et al. Regions in beta-chemokine receptors CCR5 and CCR2b that determine HIV-1 cofactor specificity. Cell 1996; 87:437-46.
19. Liao F, Alkhatib G, Peden KW, Sharma G, Berger EA, Farber JM. STRL33, a novel chemokine receptor-like protein, functions as a fusion cofactor for both macrophage-tropic and T cell line-tropic HIV-1. J Exp Med 1997; 185:2015-23.
20. Feng Y, Broder C, Kennedy P, Berger E. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein coupled receptor. Science 1996; 272:872-7.
21. Dean M, Carrington M, Winkler C, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 1996; 273:1856-62.
22. Huang Y, Paxton WA, Wolinsky SM, et al. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med 1996; 2:1240-3.
23. Liu R, Paxton WA, Choe S, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply exposed individuals to HIV-1 infection. Cell 1996; 86:367-77.
24. Samson M, Libert F, Doranz BJ, et al. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene (see comments). Nature 1996; 382:722-5.
25. Connor RI, Sheridan KE, Ceradini D, Choe S, Landau NR. Change in coreceptor use correlates with disease progression in HIV-1 infected individuals. J Exp Med 1997; 185:621-8.
26. Scarlatti G, Tresoldi E, Bjoerndal A, et al. In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression. Nat Med 1997; 3:1259-65.
27. Xiao L, Rudolph DL, Owen SM, Spira TJ, Lal RB. Adaptation to promis cuous usage of CC and CXC-chemokine coreceptors in vivo correlates with HIV-1 disease progression. AIDS 1998; 12:F137-43.
28. Zhang L, Carruthers CD, He T, et al. HIV type 1 subtypes, coreceptor usage, and CCR5 polymorphism. AIDS Res Hum Retroviruses 1997; 13:1357-66.
29. + T cell depletion in HIV-1 infected human lymphoid tissue. Proc Natl Acad Sci USA 1999; 96:663-8.
30. Shioda T, Levy JA, Cheng-Mayer C. Macrophage and T-cell line tropisms of HIV-1 are determined by specific regions of the envelope gp120 gene. Nature 1991; 349;167-9.
31. Hwang SS, Boyle TJ, Lyerly H, Cullen BR. Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1. Science 1991; 253:71-4.
32. Chesebro B, Wehrly K, Nishio J, Perryman S. Mapping of independent V3 envelope determinants of human immunodeficiency virus type 1 macrophage tropism and syncytium formation in lymphocytes. J Virol 1996; 70:9055-9.
33. + cells. Science 1995; 270:1811-5.
34. Speck RF, Wehrly K, Platt EJ, et al. Selective employment of chemokine receptors as human immunodeficiency virus type 1 coreceptors determined by individual amino acids within the envelope V3 loop. J Virol 1997; 71:7136-9.
35. Cho MW, Lee MK, Carney MC, Berson JF, Doms RW, Martin MA. Identification of determinants on a dualtropic human immunodeficiency virus type 1 envelope glycoprotein that confer usage of CXCR4. J Virol 1998; 72:2509-15.
36. Xiao L, Owen SM, Goldman I, et al. CCR5 coreceptor usage of non-syncytium-inducing primary HIV-1 is independent of phylogenetically distinct global HIV-1 isolates: delineation of consensus motif in the V3 domain that predicts CCR-5 usage. Virology 1998; 240:83-92.
37. Koito A, Harrowe G, Levy JA, Cheng-Mayer C. Functional role of the VI/V2 region of human immunodeficiency virus type 1 envelope glycoprotein gp120 in infection of primary macrophages and soluble CD4 neutralization. J Virol 1994; 68:2253-9.
38. Koito A, Stamatatos L, Cheng-Mayer C. Small amino acid sequence changes within the V2 domain can affect the function of a T-cell line tropic human immunodeficiency virus type 1 envelope gp120. Virology 1995; 206:878-84.
39. Ross TM, Cullen BR. The ability of HIV type 1 to use CCR-3 as a coreceptor is controlled by envelope V1/V2 sequences acting in conjunction with a CCR-5 tropic V3 loop. Proc Natl Acad Sci USA 1998; 95:7682-6.
40. Hoffman TL, Stephens EB, Narayan O, Doms RW. HIV type 1 envelope determinants for use of the CCR2b, CCR3, STRL33, and APJ coreceptors. Proc Natl Acad Sci USA 1998; 95:11360-5.
41. Kaufmann D, Pantaleo G, Sudre P, Telenti A, Study, SHC. CD4-cell count in HIV-1 infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Lancet 1998; 351:723-4.
42. Perrin L, Telenti A. HIV treatment failure: testing for HIV resistance in clinical practice. Science 1998; 280:1871-2.
43. Sol N, Ferchal F, Braun J, et al. Usage of the coreceptors CCR-5, CCR-3, and CXCR-4 by primary and cell line adapted human immunodeficiency virus type 2. J Virol 1997; 71:8237-44.
44. Guillon C, van der Ende ME, Boers PH, Gruters RA, Schutten M, Osterhaus AD. Coreceptor usage of human immunodeficiency virus type 2 primary isolates and biological clones is broad and does not correlate with their syncytium-inducing capacities. J Virol 1998; 72:6260-3.
45. Fätkenheuer G, Theisen A, Rockstroh J, et al. Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients. AIDS 1997; 11:F113-6.
46. Yi Y, Rana S, Turner JD, Gaddis N, Collman RG. CXCR-4 is expressed by primary macrophages and supports CCR5- independent infection by dualtropic but not T-tropic isolates of human immunodeficiency virus type 1. J Virol 1998; 72:772-7.
47. Simmons G, Reeves JD, McKnight A, et al. CXCR4 as a functional coreceptor for human immunodeficiency virus type 1 infection of primary macrophages. J Virol 1998; 72:8453-7.
48. Shioda T, Levy JA, Cheng-Mayer C. Small amino acid changes in the V3 hypervariable region of gp120 can affect the T cell line and macrophage-tropisms of human immunodeficiency virus type 1. Proc Natl Acad Sci USA 1992; 89:9434-8.
49. Marlink RG, Kanki PJ, Thior I, et al. Reduced rate of disease development after HIV-2 infection as compared to HIV-1. Science 1994; 265:1587-90.